The death of a participant in a gene therapy trial for ornithine transcarbamylase deficiency in 1999 due to immune response, as well as the uncertainty regarding these treatments resulted in a cautious approach for many years. Here, OTC is linked to hyperinsulinemic hypoglycemia, familial, 4.